Dishman Pharmaceuticals and Chemicals Limited
Add to watch list to get report alerts
BSE Code:
532526
NSE Code:
DISHMAN
Business Profile
Business Profile
Dishman Pharmaceutical & Chemicals (DISHMAN) manufactures and markets cost-effective, high quality chemical services and products to the global pharmaceutical and chemical industry. It was incorporated on June 29, 1983 as a private limited company and went public on April 1, 1996. The company got its current name On Jan. 1, 1999.
Through synthetic chemistry research, the company has developed manufacturing processes for various intermediates, active pharmaceutical ingredients (APIs), quarternary ammonium compounds (QUATS) and specialty chemicals. It is also engaged in pharmaceutical outsourcing which includes contract research and manufacturing (CRAM Segment). Presently, DISHMAN has three manufacturing sites; namely Dishman Pharmaceuticals and Chemicals (Bavla), Dishman Pharmaceuticals and Chemicals (Naroda) and Sch?tz Dishman Biotech (Bavla).
DISHMAN has marketing offices/wholly-owned subsidiaries at strategically important global locations. It has two wholly-owned subsidiaries in Europe and US called Dishman Europe and Dishman USA, Inc. The company acquired Carbogen Amcis AG (CA), a Swiss research-based company with three production facilities in Switzerland for the manufacture of high-potent, high-value products. It has representative offices in Germany, Italy and Turkey. The client list includes global pharma and agro blue chip majors. The company received the Greentech Environment Excellence Award?2006 (silver category award in chemical sector) for outstanding achievement towards environment protection and clean environment in the industrial and service industry.
The registered office of the company is at Bhadr-Raj Chambers, Swastik Cross Road, Navrangpura, Ahmedabad-380009, Gujarat.
Financials
The company reported a steep drop in standalone net profit for the quarter ended December 2008. During the quarter, the profit of the company declined 29.12% to Rs 148.96 million from Rs 210.16 million in the same quarter last year. Net sales for the quarter rose 9.35% to Rs 1095.07 million, while total income for the quarter rose 8.01% to Rs 1095.07 million, when compared with the prior year period. It posted earnings of Rs 1.85 a share during the quarter, registering 33.21% decline over previous year period.
Recent Developments
25-MAR-09
The company and Polpharma - Poland have signed a cooperation and joint API development agreement.
Future Plans
DISHMAN is putting up a medicine intermediate and quaternary alkylphosphonium salt manufacturing facility at Shanghai Chemical Industry Park, Shanghai, China. The plant is planned to be in operation by January 2008. The output of the plant will be around 3,000 MT of quaternary alkylphosphonium salts and around 500 MT of medicine intermediate.